Eye, Brain, Pain
Dompé (dompe.com) scores 79 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 64th percentile of 10195 Healthcare brands.
Dompé is an Italian pharmaceutical and biotechnology company with 130 years of industry experience. It focuses on developing innovative therapies in ophthalmology, neurology, and pain management, leveraging proprietary technologies such as rhNGF (recombinant human nerve growth factor) and the Exscalate computational drug discovery platform. The company targets clinicians, patients, and healthcare providers seeking advanced treatments for eye, brain, and pain-related conditions, positioning itself as a research-driven biotech pharmaceutical firm.
| Brand Name | Dompé |
|---|---|
| Domain | dompe.com |
| Industry | Healthcare |
| Headquarters | Italy |
| Main Competitors | Novartis (Alcon) (89/100), Santen Pharmaceutical, Bausch + Lomb (85/100), Théa Laboratories, AbbVie (Allergan) (84/100), Regeneron Pharmaceuticals (92/100) |
Moz Domain Authority 39/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #683,941 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Dompé advances research on rhNGF, its biotech pipeline and Exscalate to develop ophthalmic therapies and innovative technologies for clinicians." (Meta description: 19 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: Microdata (Schema.org), og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, GitHub; no detected presence on YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Dompé?", Claude could identify the brand as of September 2026. Dompé is an Italian biopharmaceutical company based in Milan, focused on research and development in areas like ophthalmology, rare diseases, and organ transplantation. It's known for developing biotech drugs, including treatments derived from nerve growth factor research, such a Best known for Developing cenegermin (Oxervate), a nerve growth factor-based treatment for neurotrophic keratitis, a rare eye disease.
When asked "Best brands similar to Dompé?", Claude would recommend Dompé as of September 2026. It's a notable Italian biopharma player with a distinctive focus on rare eye diseases and biotech innovation, worth mentioning in discussions of specialty pharma companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Dompé's main competitors in Healthcare: Novartis (Alcon) (89/100), Bausch + Lomb (85/100), AbbVie (Allergan) (84/100), Regeneron Pharmaceuticals (92/100).
Sources: Brand Analyzer scan
Dompé has limited AI-search visibility, scoring 35/100 on Brand Analyzer's AI visibility composite (visibility 26, trust 36, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Dompé official site
Dompé scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Dompé official site
Dompé is an Italian pharmaceutical and biotechnology company that develops innovative therapies, particularly in ophthalmology, neurology, and pain management. It combines over 130 years of pharmaceutical experience with advanced biotech research, including proprietary rhNGF technology and the Exscalate drug discovery platform.
Sources: Dompé official site
Dompé conducts pharmaceutical and biotech research to develop treatments for high-need therapeutic areas, focusing on ophthalmic therapies derived from recombinant human nerve growth factor (rhNGF). It also uses its Exscalate technology platform to support drug discovery and development for neurological and pain-related conditions.
Sources: Dompé official site
Dompé can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Dompé official site
Dompé offers ophthalmic therapies developed from its proprietary rhNGF (recombinant human nerve growth factor) technology, along with biotech pipeline treatments for neurology and pain management. It also utilizes its Exscalate platform, a technology used in drug discovery and development processes.
Sources: Dompé official site
Dompé is known for its research on rhNGF (recombinant human nerve growth factor) and its use of the Exscalate technology platform to advance ophthalmic and biotech drug development. The company is recognized as an Italian biotech pharmaceutical firm with a long-standing history in the pharmaceutical industry.
Sources: Dompé official site
Dompé's therapies and technologies are used by clinicians, patients, and healthcare providers seeking treatments for eye, brain, and pain-related conditions. The company's research and products are aimed at addressing high-need therapeutic areas within these medical fields.
Sources: Dompé official site
Dompé scores 35/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Dompé has a weak AI-visibility profile at 35/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (26/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #683,941 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 39/100 and thin schema.org structured data. In a live check, Claude could already identify Dompé from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Dompé: Dolbey Systems, Inc. (79/100), DoctorOnCall (79/100), Dorsata (79/100), Dot & Key (79/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.